Connect with us

Featured

What Curing Cancer & HIV Could Mean for This Company, Its Investors & The World!

The opportunity for companies within this sector is massive we are now talking about an industry that is currently worth over US$ 100 billion with the potential in the next 6.5 years to be worth over US$ 200 billion.

StockPrice

Published

on

GT Biopharma (GTBP) an immuno-oncology company focused on innovative treatments for cancer, based on its patent-pending TriKE™ technology has made public a recent study at the University of Minnesota which has confirmed that its HIV-TriKE™ drug platform has successfully killed patient HIV infected cells.


Get Your Free In-Depth Report on GT Biopharma (GTBP)!

Get the Company’s Latest Press Releases Delivered Right to Your Inbox As Well As Other Alerts On Public Companies!


Cancer & HIV/AIDS has a major impact on society in the United States and across the world.

[BREAKING NEWS] GT Biopharma (GTBP) Announces Solid Tumor Targeting TriKe™ Kills Non-small Cell Lung Cancer (NSCLC) Tumor Cells

Cancer.gov estimates that in 2018 1,735,350 new cases of cancer will be diagnosed & 609,640 people will die from the disease in the United States alone!

The World Health Organization estimates that as of 2017 there were 36.7 million people living with HIV globally with 1.8 million people becoming newly infected and 1 million dead of HIV-related causes.

Earlier this year MarketWatch published an article saying:

“The global oncology drugs market was valued at US$ 77.3 billion in 2018, and is projected to exhibit a CAGR of 12.3% during the forecast period (2018 – 2026).”

If these numbers are correct, this means that the global oncology drugs market could Surpass US$ 196.2 Billion by 2026.

According to an article on Fortune Business Insights” the HIV/AIDS drug market was valued at  US$ 25.3 billion in 2018 and according to the website is projected to reach US$ 40.6 billion by the end of 2026 based on a CAGR of 6.1%, between 2019-2026.

Based on this information we are now talking about an industry that is currently worth over US$ 100 billion with the potential in the next 6.5 years to be worth over US$ 200 billion.

This is a Massive Opportunity for Companies In This Space

GT Biopharma (GTBP) is a clinical-stage, immuno-oncology biotech company focused on innovative treatments based on its patent-pending TriKE™ technology. GT Biopharma (GTBP) is in good company within this space. 

Obviously you have the biotech giants:

  • Gilead Sciences, Inc. (NASDAQ:GILD)
  • Incyte Corporation (NASDAQ:INCY)
  • Merck & Co. (NYSE:MRK)

But according to a recent article that was published on The Motley Fool it may be time for investors to give their attention to the “little guys” aka the Small Cap Stocks.

Within this article, The Motley Fool talks about 3 “Out of favor” “Cancer Treatment Stocks.” One of the companies is a small-cap stock that, according to the article, “sports marquee oncology partnerships with Gilead Sciences, Incyte, as well as Merck.” 

This is a great example of a small-cap company utilizing its relationships with credible, larger entities to forward their corporate missions.

Connecting The Dots

Similarly, when investors look at GT Biopharma (GTBP) they will notice that the company is indeed a small-cap stock and like the company The Motley Fool mentioned, has ties to a large entity to help further its own corporate missions.

GT Biopharma (GTBP) has deep ties to the University of Minnesota & its prestigious Masonic Cancer Center, a comprehensive cancer center designated by the National Cancer Institute. 

The University of Minnesota is the site for the current in-human TriKE™ phase 1 clinical trial. 

In addition to being the host site for GT Biopharma (GTBP) ’s in-human clinical trial Deputy Director of the University of Minnesota’s Masonic Comprehensive Cancer Center. Dr. Jeffery Miller was hired to be GT Biopharma (GTBP) ’s Consulting Chief Medical Officer in August 2019.

To top it off on September 19, 2019, it was announced on the University of Minnesota’s website that:

University of Minnesota discovery is now a first-in-human clinical trial for leukemia & designer molecule will activate the patient’s own immune cells to attack cancer. The discovery of tri-specific natural killer engagers (TriKE™), a combination protein that bridges an immune cell and a tumor cell to drive tumor cell killing power exponentially, has led to a new Phase I, first-in-human study to treat leukemia. The study is opening exclusively at the University of Minnesota Medical Center and is being sponsored by GT Biopharma, Inc.

The relationship that GT Biopharma (GTBP) builds with the University of Minnesota and its Consulting Chief Medical Officer Dr. Jeffrey Miller continues to be a fruitful one.

On October 3, 2019 GT Biopharma (GTBP) announced that Tim Schacker, M.D., Jeffrey S. Miller, M.D., and their colleagues at the University of Minnesota presented data during a poster session held at the 18th meeting of the Society for Natural Immunity in Luxembourg discussing their design of an HIV-TriKE™ containing an antigen-binding fragment (Fab) from a broadly-neutralizing antibody targeting the HIV-Env protein. The HIV-TriKE™ is designed to target HIV while redirecting NK cell killing specifically to actively replicating HIV infected cells.

Mr. Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma, commented, “We are pleased to see how the TriKE™ technology is able to be extended to the treatment of infectious disease, and is able to kill HIV in the reservoir.”  Mr. Cataldo further stated, “We believe the HIV-TriKE™ will become part of a scalable and curative therapeutic strategy.”


Get Your Free In-Depth Report on GT Biopharma (GTBP)!

Get the Company’s Latest Press Releases Delivered Right to Your Inbox As Well As Other Alerts On Public Companies!


How Does GT Biopharma (GTBP) Measure Up Against the Competition?

GT Biopharma (GTBP) Is Developing Treatments That Stand Head-To-Head With Some Of The Industry’s Top Companies

A unique opportunity could be presenting itself for GT Biopharma (GTBP) to far surpass some of the industry’s biggest companies. 

The key to this opportunity is within the use of NK cells versus the standard “T-Cell” treatment methods.

Lose You?
Don’t Worry We’ll Explain Further…

Amgen (AMGN) – $175 Million Revenue Potential

Amgen’s T-cell cell engager was approved for marketing in December 2014. Under the branded treatment, Blincyto, Amgen’s treatment targets patients with specific types of leukemia. Where this treatment is based on T-cell therapy, it needs to activate the body’s immune system first, which could present its own list of risks. In comparison, GT BIopharma’s TriKEs/TetraKEs engage NK cells which may have potential advantages as there’s no need to “prime” the immune system. The bottom line is that even in this case, the more archaic T-cell treatment helped generate $175 million in sales in 2017 for Amgen’s Blincyto.

Gilead (GILD) And Its Acquisition of Kite Pharma – Buyout Valued At $11.9 Billion

In October 2017, Kite Pharma’s (previously publicly traded as “KITE”) therapy, Yescarta became the first CAR-T therapy approved by the FDA for the treatment of adult patients with certain types of lymphoma after two or more lines of systemic therapy. Based on this development, one of the mega-industry leaders, Gilead (GILD) bought out the company for a cool $11.9 Billion. As with the Amgen case, GT Biopharma (GTBP) NK cell platform poses even more opportunity beyond the simple T-Cell or “CAR-T” cell treatment as targeted therapies begin to take a more prominent place in cancer and immuno-oncology treatment.

Affimed (AFMD) & Roche (RHHBY) Collaboration Through Genentech – $5.9 Billion Deal

Clinical stage biopharmaceutical company Affimed (AFMD) inked a deal with a potential value of nearly $6 billion with Roche (RHHBY) company, Genentech. This is one of the clearest examples of the potential of NK cell platforms. Because these “engager-based” immunotherapeutics can treat multiple cancers, the therapies can be tailor-made for patients without having to “pre-stimulate” the body’s immune system. Not only did Affimed get an upfront payment of $96 million but with milestones, it can receive up to another $5 billion.

Meet The GT Biopharma (GTBP) Management Team

GT Biopharma (GTBP) has a management team comprised of the biotech sector’s biggest, brightest and most successful.

ANTHONY J. CATALDO

Chairman, Chief Executive Officer & President


Mr. Cataldo founded GT Biopharma Inc. upon joining the Board of Directors and subsequently Chairman and CEO in July of 2014, where he changed the Company’s profile with the inclusion of oncology assets. From February 2011 to June 2013 Mr. Cataldo served as Founder and Chairman/CEO of Genesis Biopharma, Inc., now known as Iovance Biotherapeutics, Inc., (IOVA). Mr. Cataldo created the highly successful IOVA/Genesis with the inclusion of assets acquired from the National Cancer Institute for the treatment of stage four melanoma. Mr. Cataldo has extensive experience in the biotechnology sector having served as Chairman/CEO of several biotech companies including: Calypte Biomedical Corporation, and Senetek, PLC.

JEFFREY S. MILLER, M.D.

Consulting Chief Medical Officer


Jeffrey S. Miller, MD, received a Bachelor of Science degree from Northwestern University in Evanston, Illinois and received his MD from Northwestern University School of Medicine. He completed an internship and residency in Internal Medicine at the University of Iowa in Iowa City. After completing a post-doctoral fellowship in Hematology, Oncology and Transplantation at the University of Minnesota, he joined the faculty in 1991. Dr. Miller is currently a Professor of Medicine at the University of Minnesota. He is the Deputy Director of the University of Minnesota Masonic Comprehensive Cancer Center. He has more than 20 years of experience studying the biology of NK cells and other immune effector cells and their use in clinical immunotherapy with over 170 peer-reviewed publications. He is a member of numerous societies such as the American Society of Hematology, the American Association of Immunologists, a member of the American Society of Clinical Investigation since 1999. He serves on the editorial board for Blood and is a reviewer for a number of journals and NIH grants.

STEVEN WELDON

Chief Financial Officer & Director


Mr. Weldon has extensive experience with GT Biopharma (GTBP) having served on the Board of Directors from September 2014 through October 2018. He also served as Chief Financial Officer of GT Biopharma (GTBP) from November 2014 through October 2018. Mr. Weldon has over 16 years of financial and accounting experience. Mr. Weldon’s financial background includes experience in managerial, private accounting and planning. He has served on the board of several publicly traded companies as both, chief executive officer and chief financial officer. For several years, he taught accounting and tax courses to undergrad students at Florida Southern College. He received his bachelor of science degree and his Master’s in Business Administration from Florida Southern College and is a licensed Certified Public Accountant in the State of Florida.

How Does GT Biopharma (GTBP) Measure Up Against the Competition?

  1. GT Biopharma (GTBP) is operating within a space that is currently valued at US$ 100 billion and is estimated to be valued at US$ 200 billion by 2026. This is a massive growth opportunity.
  2. GT Biopharma (GTBP) has made public a recent study at the University of Minnesota which has confirmed that its HIV-TriKE™ drug platform has successfully killed patient HIV infected cells.
  3. GT Biopharma’s (GTBP) deep ties with the University of Minnesota & its Masonic Cancer Center, its Deputy Director & now GT Biopharma’s (GTBP) Consulting Chief Medical Officer Dr. Jeffery Miller give the company a huge advantage.
  4. GT Biopharma (GTBP) is developing treatments that stand head-to-head with some of the industry’s top companies.
  5. GT Biopharma (GTBP) has a management team comprised of some of the biggest, brightest and most successful professionals within the biotech sector.

Get Your Free In-Depth Report on GT Biopharma (GTBP)!

Get the Company’s Latest Press Releases Delivered Right to Your Inbox As Well As Other Alerts On Public Companies!


Sources

https://www.marketwatch.com/press-release/global-oncology-drugs-market-to-surpass-us-1962-billion-by-2026-2019-01-30

https://www.fortunebusinessinsights.com/industry-reports/hiv-aids-drugs-market-101115

https://www.cancer.gov/about-cancer/understanding/statistics

https://www.who.int/features/qa/71/en/

https://www.fool.com/investing/2019/10/10/3-cancer-treatment-stocks-to-buy-right-now.aspx

https://www.gtbiopharma.com/news-media/press-releases/detail/173/gt-biopharma-hires-chief-medical-officer-jeffery-miller

https://www.cancer.umn.edu/node/17706https://finance.yahoo.com/quote/GTBP?p=GTBP&.tsrc=fin-srch


Disclaimer:

Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer.

Continue Reading
Click to comment

Featured

Stock Price Newsletter – November 15, 2019

Joe Samuel

Published

on

best biotech stocks to trade now

3 Biotech Stocks To Watch As The Sector Heats Up

When it comes to building a portfolio, money managers almost always ask their clients to diversify their portfolio. That’s in order to hedge against market risks. Hence, an investor needs to explore a wide range of sectors and choose stocks from those. One of the hottest sectors lately is the biotech sector.

Continue Reading


Comcast (CMCSA) Enters The Streaming Business: How Far Can It Go?

There had been a lot of anticipation with regard to the ‘streaming wars’ for most of the year. At least it’s here, with the launch of Apple TV+ (AAPL) and Disney Plus (DIS). However, those two launches simply signify the commencement of the streaming wars.

See For Yourself


3 Pharma Stocks to Watch As The Sector Gets Attention In November

It is often noticed that investment experts ask people to diversify their money across sectors. More often than not, it is recommended that some attention should be allocated towards biotech stocks. The simple reason behind this is the fact that biotech stocks have proven to be fruitful companies and the sector continues to churn out winners.

Click To Read More

Continue Reading

Biotechnology

3 Biotech Stocks To Watch As The Sector Heats Up

A. Lawrence

Published

on

top biotech stocks to watch list

When it comes to building a portfolio, money managers almost always ask their clients to diversify their portfolio. That’s in order to hedge against market risks. Hence, an investor needs to explore a wide range of sectors and choose stocks from those. One of the hottest sectors lately is the biotech sector.

It has managed to generate impressive growth over the past decade and remains a potentially high growth space for investors. On that note, here is a quick look at two biotech stocks that should be tracked by investors.

Biotech Stocks To Watch #1: GT Biopharma (GTBP)

GT Biopharma (GTBP) is a clinical-stage, immuno-oncology biotech company focused on innovative treatments based on its patent-pending TriKE™ technology. GT Biopharma (GTBP) is in good company within this space. Obviously you have the biotech giants:Gilead Sciences, Inc. (NASDAQ:GILD), Incyte Corporation (NASDAQ:INCY), &Merck & Co. (NYSE:MRK). But according to a recent article that was published on The Motley Fool it may be time for investors to give their attention to the “little guys” aka the Small Cap Stocks.

Within this article, The Motley Fool talks about 3 “Out of favor” “Cancer Treatment Stocks.” One of the companies is a small-cap stock that, according to the article, “sports marquee oncology partnerships with Gilead Sciences, Incyte, as well as Merck.” 

top biotechnology stocks to watch today

Similarly, when investors look at GT Biopharma (GTBP) they will notice that the company is indeed a small-cap stock and like the company The Motley Fool mentioned, has ties to a large entity to help further its own corporate missions. GT Biopharma (GTBP) has deep ties to the University of Minnesota & its prestigious Masonic Cancer Center, a comprehensive cancer center designated by the National Cancer Institute. Thanks to this relationship, GT Biopharma has been able to capitalize on several key developments:

GT Biopharma (GTBP) announces that Tim Schacker, M.D., Jeffrey S. Miller, M.D., and their colleagues at the University of Minnesota presented data showing its HIV-TriKE™ was able to kill HIV infected cells in the reservoir

GT Biopharma (GTBP) Announces Solid Tumor Targeting TriKe™ Kills Non-small Cell Lung Cancer (NSCLC) Tumor Cells

Read more on GT Biopharma Here.

Biotech Stocks To Watch #2: Jaguar Health (JAGX)

The first biotech stock to consider is that of Jaguar Health Inc (NASDAQ:JAGX), which made a major announcement at the end of October. That has resulted in the major rally in the stock through November and so far, the stock has gained as much as 45%. The company had announced that its fully owned subsidiary Napo Pharmaceutical has agreed on a distribution agreement with TannerGAP.

TannerGAP is part of the larger Tanner Pharma Group and will distribute the product Mytesi in places at which it is not yet registered. At this point in time, Mytesi is registered in Israel, the United States and Canada. Recently Jaguar also appointed Ian Wendt as its Vice President of Commercial Strategy.

On November 14 the company announced that Georgetown University ‘s Data Safety Monitoring Committee (“DSMC”) has reviewed the interim analysis for futility for the third-party, investigator-initiated Phase 2 HALT-D study evaluating the effectiveness of Mytesi® (crofelemer) for symptomatic relief in HER2 positive breast cancer patients receiving chemotherapy with trastuzumab, pertuzumab, and docetaxel or paclitaxel or trastuzumab, pertuzumab, carboplatin, and docetaxel (the “Study”). The DSMC has notified the Principal Investigator that the Study is allowed to enroll to completion. Enrollment in the Study now exceeds 85%, and the treatment period for each patient is 3 months.

SPECIAL REPORT | What Curing Cancer & HIV Could Mean for This Company, Its Investors & The World!

Biotech Stocks To Watch #3: Therapix Biosciences (TRPX)

The other biotech stock that warrants attention is that of Therapix Biosciences Ltd (NASDAQ:TRPX). The company is involved in developing treatments that are CBD based and today it announced top line results from the Phase 2A clinical study of its product THX-110. The study revealed that the product did, in fact, have a positive effect on patients who are afflicted with obstructive sleep apnea (OSA).

The study was conducted at the Assuta Hashalom Medical Center located in Israel and it represents a major positive for Therapix. After the news broke, the rocketed by as much as 19.45% and has emerged as one of the biotech stocks to watch for the rest of the week.

SPECIAL REPORT | What Curing Cancer & HIV Could Mean for This Company, Its Investors & The World!

best penny stocks Clovis Oncology (CLVS)

Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer.

Continue Reading

Entertainment

Comcast (CMCSA) Enters The Streaming Business: How Far Can It Go?

Joe Samuel

Published

on

stock market today

There had been a lot of anticipation with regard to the ‘streaming wars’ for most of the year. At least it’s here, with the launch of Apple TV+ (AAPL) and Disney Plus (DIS). However, those two launches simply signify the commencement of the streaming wars.

Comcast To Launch Own Streaming Service in 2020

comcast peacock

NBC Universal, owned by Comcast Corporation (NASDAQ:CMCSA), is all set to launch its own streaming service named Peacock in April next year and it is interesting to figure where it is going to stand with regards to the streaming wars. As everyone knows, content and pricing are the most important factors in this regard. Here is a closer look at Peacock.

According to reports, Peacock is apparently going to launch with as much as 15,000 hours worth of content for its users and it is also going to include such cult classic shows like ‘The Office’. More often than not, streaming services need a few ‘anchor shows’ in order to attract users and that seems to be in place at Peacock.

[MARKET PREVIEW] The $40 Billion Dollar Content Gold Rush

Content Providers Eager To Capitalize

Fearless Films Inc. (FERL) is a full-service production company with award-winning upper management. The company specializes in producing both short and feature films as well as scriptwriting and distribution.

Fearless Films has been developing its operations recently which has caught the interest of new investors. One development was a recent news press relating to an agreement with Victor Altomare, the Founder and President of Fearless. The company entered a Letter of Intent to acquire the rights of up to 12 movies from a library held by Mr. Altomare. The price of the acquisition is to be determined at a later date.

streaming cord cutting entertainment stocks

On October 31, Fearless Films (FERLannounced that further to its initial press release on the 16th, the Company has selected The Lunatic as the first film to be selected for appraisal and final negotiation. Fearless will engage an international accounting and advisory firm with a strong film industry practice to provide an independent valuation of the film, following which the company will enter into final negotiations on the purchase.

Companies like Fearless are looking to fill the content needs of companies streaming companies. Jeffrey Cole explained how Apple, for example, needs new content, “I think entertainment’s going to become a key element of Apple’s business. For them, spending $2 billion on [original content] is just dabbling. If they like what they see, I think they’ll have a $10 billion budget.” This is a massive market potential that Fearless Films is looking to capitalize on.

[MARKET PREVIEW] The $40 Billion Dollar Content Gold Rush

What’s In Store For Peacock?

However, it is highly interesting to note that Peacock is going to make an ad-supported free version of the platform available. Initially, it was supposed to be an option for Comcast cable or broadband customers only.

This pricing structure could throw the other companies into chaos, considering no one in the industry offers a free version at this point. Peacock expects to generate $5 per month per user from the free version. Apple TV+ is priced at $4.99 per month but it is free 12 months for users who have purchased a new Apple device. Disney Plus, on the other hand, is priced at $6.99 a month.

A yearly subscription will cost $69.99 a month. Another heavyweight that is going to join the arena in a few months is HBO Max and that is going to set back a customer $14.99 on a monthly basis. However, HBO Max will be available for free for AT&T customers. So, it is clear that the streaming space is heating up and Peacock has come up with a very interesting plan to make a mark.

movie stocks

Pursuant to an agreement between Midam Ventures LLC and Fearless Films Inc. (FERL), Midam has been paid $94,980 by Fearless Films Inc. (FERL) for a period from October 1, 2019 to November 17, 2019. We may buy or sell additional shares of Fearless Films Inc. (FERL) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Fearless Films Inc. (FERL). Click Here For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com

Enter Your Email Address & Name Below to Receive Your Free Report on (GTBP)

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com